RxDoctor Payments DataLook up a doctor →

Johnny Hickson, MD

Urology · Oklahoma City, OKNPI 1528295755

Payments from drug & device makers

$15,774in general payments, 2019–2025

Across 569 payments — averaging $27.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$4K
  • Procept Biorobotics Corporation$2K
  • Astellas Pharma US Inc$1K
  • AbbVie$1K
  • Coloplast$870
  • Pfizer$763
  • plus $6K from 44 others

What the payments were for

  • Speaking & faculty fees$3502%
  • Travel & lodging$8015%
  • Food & beverage$14,53592%
  • Education$881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,774 in reported general payments places this provider in the 85th percentile of 145 urology providers in Oklahoma.

See all urology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$618,222
Medicare patients
689
Services billed
13,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide13$187,515
MyrbetriqMirabegron150$137,018
Thiola EcTiopronin12$88,426
GemtesaVibegron75$58,018
Tamsulosin Hcl555$9,727
Alfuzosin Hcl ErAlfuzosin Hcl187$6,624
Finasteride256$5,280
Testosterone31$4,180
Solifenacin Succinate78$3,450
Estradiol37$2,563
Silodosin24$2,539
Tolterodine Tartrate ErTolterodine Tartrate39$2,456
Testosterone Cypionate62$1,918
Potassium Citrate ErPotassium Citrate12$1,461
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst34$1,108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,484$324,533163 claims
Sumitomo Pharma America, Inc.Gemtesa$385$58,01875 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 145 urology providers in Oklahoma.

Other urology in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →